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Abstract
High risk human papillomaviruses are squamous epitheliotropic viruses that may cause cervical and other cancers. HPV
replication depends on squamous epithelial differentiation. Transformation of HPV-infected cells goes along with
substantial alteration of the viral gene expression profile and preferentially occurs at transformation zones usually at the
uterine cervix. Methylation of the viral genome may affect regulatory features that control transcription and replication of
the viral genome. Therefore, we analyzed the methylation pattern of the HPV16 upstream regulatory region (URR) during
squamous epithelial differentiation and neoplastic transformation and analyzed how shifts in the HPV URR methylome may
affect viral gene expression and replication. HPV 16 positive biopsy sections encompassing all stages of an HPV infection
(latent, permissive and transforming) were micro-dissected and DNA was isolated from cell fractions representing the basal,
intermediate, and superficial cell layers, each, as well as from transformed p16
INK4a-positive cells. We observed fundamental
changes in the methylation profile of transcription factor binding sites in the HPV16 upstream regulatory region linked to
the squamous epithelial differentiation stage. Squamous epithelial transformation indicated by p16
INK4a overexpression was
associated with methylation of the distal E2 binding site 1 leading to hyper-activation of the HPV 16 URR. Adjacent normal
but HPV 16-infected epithelial areas retained hyper-methylated HPV DNA suggesting that these viral genomes were
inactivated. These data suggest that distinct shifts of the HPV 16 methylome are linked to differentiation dependent
transcription and replication control and may trigger neoplastic transformation.
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Introduction
Human papillomaviruses are small epitheliotropic DNA viruses
that infect squamous cell epithelia of the skin (skin types) and
mucosal (mucosa types) surfaces and may cause hyper-proliferative
lesions as for example common or genital warts. High risk HPV
types (HR-HPVs) are associated with a variety of human cancers
particularly of the uterine cervix [1]. Infections with these viruses
are extremely widespread among young men and women [2] while
related cancers predominantly emerge from few infected basal
cells predominantly at the transformation zone of the uterine
cervix. These observations strongly suggest that not only the
infection of epithelial cells but also mechanisms that govern viral
gene expression patterns within the host cells contribute to the
control of the papillomavirus life cycle and HR-HPV-related
transformation [3–5].
The viral genome consists of a double stranded circular DNA
molecule that encompasses a set of 6 early genes (E6, E7, E1, E2,
E4, E5) that are involved in viral gene expression and replication
control, whereas two late genes (L1 and L2) encode the major
capsid proteins. During a permissive infection the virus is thought
to first infect distinct basal cells [6], where it may reside in a
‘‘silenced’’ or ‘‘latent’’ stage [7]. Some of the initially infected basal
cells may enter a permissive life cycle during that offspring viral
genomes are replicated in the differentiated squamous cell layers.
Finally mature virions are released at the surface of the epithelium.
It is not known so far how many of the initially infected cells ever
enter the permissive viral life cycle. It may well be that even the
majority of infections may end as abortive silenced or latent
infections during that no major viral gene expression is ever
initiated. Such infections if they occur would not cause any
pathology and hence would clinically remain unnoticed.
During a permissive infection in a single infected basal cell the
virus appears to express the genes E6 and E7 in a highly controlled
pattern that allows for limited local expansion of the respective
infected basal cell [8]. Upon infection of the basal cells, HPV
genomes are replicated up to 50–100 copies per cell. Following this
initial establishment phase, it apparently replicates along with host
cell chromosomes, however, without triggering productive viral
genome replication as long as these cells remain in the basal or
parabasal cell layer. Throughout this maintenance phase in
undifferentiated squamous epithelial cells, viral genes are ex-
pressed at low levels. Once these cells leave the basal cell layer they
differentiate into intermediate squamous epithelial cells. Here, the
transcriptional activity of the HPV early genes is substantially
increased [8]. This retains the respective cells in a mode capable
for DNA replication and triggers replication of the viral genomes
[3,8]. Upon further squamous epithelial differentiation these cells
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off, whereas the two late genes (L1 and L2) become strongly
activated (early - late shift) and allow for capsid formation,
packaging of the replicated viral genomes and release of mature
HPV virions. This complex differentiation dependent viral gene
expression and replication mode implies that expression of viral
genes is tightly regulated along with squamous epithelial
differentiation [9].
Malignant transformation of HR-HPV-infected cells preferen-
tially occurs in cells at the uterine transformation zone. It is usually
preceded by characteristic squamous epithelial precursor lesions
during that the above outlined viral gene expression pattern is
fundamentally changed. The shift from a permissive HPV
infection towards cellular transformation is characterized by
substantially increased expression of the viral oncogenes E6 and
E7 in basal and parabasal cells [10,11].
Recent work has shown that the overexpression of E7 is
accompanied by substantial over-expression of the cyclin-depen-
dent kinase inhibitor p16
INK4a that is therefore used as biomarker
for HPV-transformed epithelial cells [12–14]. The shift from
permissive to transforming HR-HPV-infections is regarded as the
key event and the rate limiting step in HPV-mediated cellular
transformation and carcinogenesis [15]. Several lines of evidence
suggested that integration of the HPV genome and disruption of
the E2 open reading frame results in loss of the E2 negative
regulatory function [16]. However, this concept is in contradiction
with findings that demonstrate that many of the fully malignant
HPV-associated cancers do not even carry any integrated viral
genome copies [17–20]. High-grade cervical lesions that encom-
pass integrated viral genomes also carry episomal viral genomes
that should be capable to encode the E2 gene product [17].
Integration thus rather seems to be the consequence of
chromosomal instability mediated by the deregulated expression
of the viral E6 and E7 genes instead of its cause [19,21].
Thus, if deregulated expression of the E6 and E7 genes and
hence the transforming expression mode is considered to be the
initiating event of HPV-induced carcinogenesis, it is reasonable to
assume that the shift from permissive to transforming infections
substantially precedes integration of viral genomes.
Control of gene expression by epigenetic modification of distinct
DNA sequences is a fundamental biological process that impacts
crucial biological features such as embryonic development, cellular
differentiation and aging [22–26]. Changes of the epigenetic
modification of distinct genes are associated with major human
diseases and in particular carcinogenesis [27,28]. Methylation of
HPV genomes have been analyzed in a series of recent
publications [29–40]. The general observation was that the degree
of methylation of the HPV genomes was consistently higher at
most sites in carcinomas as compared to dysplastic precancerous
lesions. Further data on the influence of DNA methylation in the
HPV life cycle came from the studies that focused on methylation
of the E2 binding sites (E2BSs) in the HPV 16 URR. [41,42]. The
E2 protein is an important transcriptional regulator of the HPV
genome. It mediates its transcriptional control functions through
binding to four distinct E2BSs located within the URR. The
capacity of the E2 protein to bind E2BSs in vitro is inhibited by
methylation of CpG dinucleotides within these E2BSs [43] and
therefore inhibits transcriptional activation by the E2 protein [42].
Methylation analysis of E2 binding sites within URR in
immortalized HPV-infected epithelial cells (W12 cells) demon-
strated that these regions are hypo-methylated upon differentiation
in vitro [41,42]. These observations suggest that the methylation
state of the viral genome, and particular that of E2BSs, may vary
during the viral life cycle and thus squamous epithelial
differentiation. However, the molecular impact of the methylation
pattern of HPV genomes during the various stages of the HPV life
cycle and also cellular transformation remained largely obscure.
To fill this gap of knowledge we analyzed for the first time the
methylation status of the HPV 16 URR in different phases of the
viral life cycle linked to distinct phases of the squamous epithelial
differentiation pattern in naturally occurring cervical lesions.
Specifically, we analyzed the methylation status of CpG
dinucleotides in transcription factor binding sites within the
HPV 16 URR using DNA preparations isolated from microdis-
sected squamous epithelial cell layers, reflecting basal, intermedi-
ate and superficial squamous cell differentation. In addition, we
compared the methylation status of the HPV 16 URR in cells that
have already undergone the switch to the transformed phenotype




To test the hypothesis that differential methylation of the viral
genome regulates its expression, we analyzed modifications of the
methylation status of all CpG dinucleotides in the viral upstream
regulatory region (URR) during epithelial differentiation and
transformation. Therefore, we selected in a first approach from a
large histopathology archive tissue sections of 3 HPV 16 positive
samples that encompassed representative parts of all different
stages of an HPV-infection (Figure 1, Figures S1, S2, S3, S4, S5,
S6, S7, S8, S9, S10). These included: i.) HPV infected epithelium
without any morphological changes and no obvious signs of viral
replication [44,45], ii.) cervical intraepithelial low grade lesions
(sometimes referred to as flat condylomas) lacking diffuse p16
INK4a
immuno-reactivity but displaying koilocytes or HPV 16 L1 capsid
protein expression in superficial squamous cells as indicator for
permissive HPV-infections and iii.) high-grade lesions with diffuse
p16
INK4a immune reactivity as indicator of transforming HPV 16
infections [12,13].
These tissue sections from three independent lesions were
micro-dissected and DNA was isolated from cell fractions
representing the basal, intermediate, and superficial cell layers
(Figure 2, upper and middle panels; Figures S1, S2, S4, S6, S7 and
S9), as well as from transformed p16
INK4a-positive cells (Figure 2,
lower panel, right image; Figures S1, S3, S5, S8 and S10). DNA
was extracted from each individual microdissected cell sample,
treated with sodium bisulfite and amplified with 3 primer pairs
covering the HPV16 URR region and analyzed by bisulfite
genomic sequencing techniques and the modified Combined
Bisulfite Restriction Analysis (COBRA) [46].
Methylation of the HPV16 URR in latent and permissive
infection modes
The analyzed region of HPV16 URR between genomic
positions 7198 and 161 contains in total 16 CpG dinucleotides
(Figure 3, 4 and 5). It encompasses 3 functionally distinct segments
that have been referred to as the 59 LCR, the enhancer, and the
promoter (Figure 3, 4 and 5). The 59LCR contains 4 CpG
dinucleotides including 2 CpGs within the E2BS1. The enhancer
contains five CpG dinucleotides including 4 CpG dinucleotides
within NFI and TEF-1 binding sites (NFIBS, TEF-1BS). The
promoter retains seven CpG dinucleotides, six of which are
located within a Sp1 or E2 binding sites (E2BS2, E2BS3, and
E2BS4).
In squamous epithelial areas that did not display any
histopathologic abnormalities (Figure 2, upper panel; Figures S4,
S6 and S9) and did not show signs of viral gene expression, all 16
The HPV-Methylome in the HPV Life Cycle
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whole thickness of the epithelium (Figure 3 and 6). In epithelial
areas that display koilocytes and express the L1 capsid protein as
histopathologic correlate of permissive HPV infections (Figure 2,
middle panel; Figures S1, S2 and S7) [45] the consistent
methylation pattern observed in the adjacent normal tissues was
substantially changed into a more complex pattern (Figure 4 and
6). The promoter region of DNAs isolated from the basal or
intermediate cell layers consistently contained unmethylated
CpGs. In the superficial cells, however, most of the CpG
dinucleotides of the promoter region were methylated including
the E2BSs 2, 3, and 4 as well as the one in the SP1 site. The 4
CpG dinucleotides of the enhancer region including the ones
within two NFIBSs and one TEF-1BS were heavily methylated in
basal cells but to a lesser extent in the more differentiated
intermediate cells (Figure 4 and 6). In the 59LCR segment all 4
CpG dinucleotides were unmethylated irrespective of the differ-
entiation stage (Figure 4 and 6). Interestingly, the E2BS1 was not
methylated in basal, intermediate or superficial squamous
epithelial cells during this early stage of the infection.
Methylation of the HPV16 URR in the transforming
infection mode
To determine whether transformation of HPV-infected cells is
also linked to changes of the methylation pattern of distinct CpG
dinucleotides within the HPV16 URR, we microdissected
p16
INK4a immunoreactive cells from the same sections (Figure 2,
lower panel, right image; Figures S1, S3, S5, S8 and S10) and
analyzed the DNA methylation pattern by bisulfite sequencing
(Figure 5 and 6). In these cells the 4 CpG dinucleotides within the
NFI-BS and the TEF-1BS of the enhancer region were methylated
and 7 CpG dinucleotides of the promoter were de-methylated.
However, in contrast to the p16
INK4a-negative areas with
permissive infection, 3 CpG dinucleotides in the 59LCR including
the 2 CpG dinucleotides within the E2BS1 were consistently
methylated. In addition to these three lesions we further included 2
more lesions displaying diffuse p16
INK4a expression and confirmed
the latter observation (Figure 5, samples 4 and 5).
To confirm the specific methylation of the E2BS1 in the
p16
INK4a-positive transformed cells detected by bisulfite genomic
sequencing, we analyzed the methylation status of 2 CpG
dinucleotides within the E2BS1 in additional 34 p16
INK4a-positive
high-grade cervical dysplastic lesions (CIN2 and CIN3) and the
corresponding p16
INK4a-negative control tissues of the same
sections using the modified Combined Bisulfite Restriction
Analysis (COBRA). Methylation of the CpG dinucleotide within
the E2BS1 was detected in HPV genomes of 30 of 34 (88%)
p16
INK4a-positive lesions but only 6 of 34 (17,6%) HPV genomes
isolated from p16
INK4a-negative tissues.
Effect of E2BS1 methylation on the p97 promoter activity
The HPV DNA methylation analysis presented above indicated
that the CpG dinucleotides within the E2BS1 were almost
exclusively methylated in p16
INK4a-positive high-grade lesions
pointing to a functional relevant impact of this specific methylation
pattern in HPV-mediated cell transformation. To test whether
methylation of these CpG dinucleotides within the E2BS1 is
responsible for activation of the early p97 promoter observed
Figure 1. Schematic outline of the recruitment of lesions included into the study. 34 HPV 16 infected cervical lesions were recruited from a
gynecopathology archive of cervical punch and cone biopsies. Sections of these lesions were stained with H&E, p16
INK4a and L1. 11 of these displayed
koilocytes and L1 positive superficial squamous epithelial cells. Of these lesions, three showed a continuum of p16
INK4a-positive epithelial areas
indicating transforming HPV infections. 2 additional biopsies displaying p16
INK4a-positive epithelial areas were recruited from other biopsies not
directly showing this continuum of intra-lesional progression for the in depth methylation analysis as shown in Figure 5.
doi:10.1371/journal.pone.0024451.g001
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aimed to determine potential functional implications of methyla-
tion of these CpG dinucleotides on the activity of the p 97
promoter in transient transfection experiments. The methylated
sequences were obtained by PCR as described in material and
methods section. In addition, two single-base substitutions in
E2BS1 were introduced into the wild-type HPV16 LCR. HPV-
negative C33A cells were co-transfected with increasing amounts
of an expression vector for HPV16 E2 and a reporter plasmid
containing either the entire HPV16 LCR in front of the luciferase
gene (wtE2BS1), the LCR with mutations in the E2BS1
(mutE2BS1), or a LCR that was methylated in the E2BS1
(methE2BS1) (Figure 7A). Co-transfection of increasing amounts
of the HPV16 E2 expression vector and the reporter construct,
wtE2BS1, showed that the p97 promoter was activated by small
amounts of HPV16 E2 (Figure 7B). Increasing amounts of HPV16
E2 reduced the promoter under control of the wild-type LCR.
Methylation of the E2BS1 significantly induces the luciferase
activity in the presence of low amounts of E2, followed by a dose-
dependent repression (Figure 7B). The impact of methylation of
the E2BS1 was most obvious while using 200 ng of the E2
expression vector. The wild type promoter was 1.9 fold activated,
whereas the methylated promoter yielded a 4.8 fold activation. As
expected, for the plasmid with CRT mutation in CpG
dinucleotides within E2BS1 (mutE2BS1), only slight induction of
luciferase activity was observed in the presence of low amounts of
E2 expression vector.
To exclude that this effect of the methylation of the E2BS1 on
the p97 promoter activity depends on the cell type (C33A cells)
that was used we repeated these experiments using normal human
foreskin keratinocytes for transient transfection experiments. Here,
again we observed strong activation of the p97 promoter while
using the construct with the methylated E2BS1 (Figure 7C).
Next we aimed to test these regulatory features under
experimental conditions in that E2 expression was driven by the
same genome controlled by the p97 early promoter as it is seen in
the natural situation. We therefore used quantitative real time
PCR to measure the amount of E6 transcripts transcribed from
full-length HPV 16 genome with either unmethylated wild type
(wtE2BS1) or methylated (methE2BS1) CpG dinucleotides in the
E2BS1 upon transfection of the respective plasmids into human
primary foreskin keratinocytes (Figure 7D). The amount of E6
transcripts was determined from total RNA preparations extracted
from cells 24, 48 and 72 hours after transfection. The results show
a 2.6, 4.8 and 5.2-fold increase in E6 transcript levels for genomes
carrying the methE2BS1 compared to genomes with wtE2BS1
genomes after 24, 48 and 72 hours, respectively (Figure 7E). These
experiments thus confirmed the results obtained in the co-
transfection experiments (Figure 7B and 7C) indicating that
methylation of the CpG dinucleotides within the E2BS1 result in
substantial activation of the promoter activity of the p97 promoter.
Binding of alternate transcription factors to the
methylated E2BS1
An earlier report by Thain et al. suggested that E2 does not bind
to methylated E2BSs [43]. However our data revealed that the
promoter activity of constructs encompassing methylated CpG
dinucleotides in the E2BS1 was substantially enhanced if
Figure 2. Microdissection of cervical tissues representing latent, permissive, and transforming modes of HPV infection. Laser
microdissection of paraffin-embedded section containing areas with: HPV 16 infected epithelium without any morphological changes (normal),
permissive infections (i.e. cervical intraepithelial low grade lesions lacking diffuse p16
INK4a immuno-reactivity but displaying koilocytes), and adjacent
transforming infections (CIN 3 lesions with diffuse p16
INK4a immune reactivity). This tissue sections were micro-dissected and DNA was isolated from
cell fractions representing the basal, intermediate, and superficial cell layers, as well as from transformed p16
INK4a-positive cells.
doi:10.1371/journal.pone.0024451.g002
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co-expressed E2 (Figure 7B and 7C). We therefore hypothesized
that additional cellular factors may be involved in the E2-mediated
regulation of the p97 promoter activity via either the methylated
or unmethylated E2BS1.
We used EMSA analyses with nuclear cell extracts isolated from
different HPV-negative squamous epithelial cell lines (normal
foreskin keratinocytes, C33A, HT3) to test whether differential
methylation of the two CpG dinucleotides within the (E2BS1)
results in binding of alternate transcription factors to the
methylated in comparison to the unmethylated E2BS1. Methyl-
ated and unmethylated DNA probes spanning the regions at nt
7444–7468 were 39 end-labeled with biotin. The methylated
probes showed three shifted bands (Figure 7F, lines 4, 6). In
contrast, unmethylated probes were not shifted by any of the
nuclear extracts (Figure 7F, lanes 3, 5). Competition experiments
were performed with full-length, non-labeled probes as illustrated
in Figure 7F (lines 7, 8). Binding to the methylated probe was
competed by pre-incubation with a 100-fold excess of a
methylated oligonucleotide (Figure 7F, lane 8), suggesting that a
yet uncharacterized protein complex binds specifically to this
methylated sequence.
The EMSA experiments indicate that a complex of not yet in
detail characterized proteins apparently bind to the region of
methylated E2BS1, but fails to bind to the unmethylated E2BS1.
This experiment supports the hypothesis that binding of cellular
factor(s) might be substantially influenced by the methylation
status of respective CpG dinucleotides. Therefore, methylation of
the E2BS1 (Figure 5) of the HPV 16 URR observed in the
transforming mode of HPV-infection (p16
INK4a-positive lesions)
may have a direct influence on the transcriptional activity of the
HPV 16 URR by binding of a yet uncharacterized complex of
transcription factors.
Discussion
Previous reports suggested that the HPV genome is differentially
methylated during progression from simple infected to trans-
Figure 3. Differentiation dependent HPV16 URR methylation in the latent infections. The methylation status of the HPV16 URR was
determined by bisulfite treatment followed by direct DNA sequencing of amplified DNA fragments using 3 sets of primers covering the complete
HPV16 URR as indicated by the blue arrows in the upper part of the Figure. DNA derived from laser-microdissected basal, intermediated and
superficial layers of the cervical normal HPV 16 infected epithelium was amplified and cloned. 12 individual clones were sequenced to identify the
presence and patterns of the methylated CpG dinucleotides. The Figure visualizes schematically the methylation of 16 CpG dinucleotides (positions
from 7198 to 161) in the URR of HPV-16 genomes. The analyzed region encompasses 3 functionally distinct segments that have been referred to as
the 59 LCR, the enhancer, and the promoter. Open circles represent an unmethylated CpGs, filled circles represent methylated CpGs.
doi:10.1371/journal.pone.0024451.g003
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tial methylation of the viral genome may somehow be involved in
the regulation of viral gene expression and possibly also replication
control. Alterations of the HPV-methylome were observed
particularly in the URR and L2 and L1 gene in high grade pre-
cancer and invasive cancer suggesting that the lack of expression of
these genes may be attributed at least in part to increasing
methylation of the respective parts of the viral genomes
[29,34,35,37,40,47–49]. The E2BS2 to 4 were also found to be
increasingly methylated in more advanced dysplasia or invasive
carcinomas [34–37,40]. Although it has not been analyzed in
detail, the increased methylation pattern in some of those studies
might well be explained by integration of the viral genomes into
the host cell chromosomes. Genomic integration of viral genomes
has been repeatedly shown to be associated with hyper-
methylation of the viral genomes in the integrated context
[35,38,50,51].
The permissive life cycle of HPV is restricted to preneoplastic
lesions and essentially coupled to squamous epithelial differenti-
ation. In this report we for the first time used DNA isolated from
microdissected squamous epithelial cells reflecting various differ-
entiation conditions of HPV-infected squamous epithelial cells of
the uterine cervix. These included a.) normal squamous epithelium
adjacent to lesions induced by HPV 16 infections, b) areas of active
viral replication reflected by koilocytes or the production of
mature viral particles as indicated by HPV L1 expression in the
superficial squamous epithelial cell layers, and c.) areas of the
neoplastic transformation of the squamous epithelial host cells
indicated by the strong over-expression of the cyclin dependent
kinase inhibitor p16
INK4a [12,13].
The data described here reveal three major novel findings. 1.)
There are epithelial cells adjacent to HPV 16 induced cervical
lesions that do not show any evidence of an ongoing HPV
infection (Figure 2, Figures S4, S6, and S9) but carry viral genomes
methylated in all 16 CpG dinucleotides of the HPV 16 URR
analyzed (Figure 3 and 6). This finding strongly suggests that the
extensive methylation of the HPV 16 genome in these cells
prevents viral gene expression and replication, rendering the viral
genomes inactive or ‘‘silent’’ passengers in these cells without
causing any cytopathic effects.
Figure 4. Differentiation dependent HPV16 URR methylation in the permissive infections. The methylation status of the HPV16 URR
determined by bisulfite treatment followed by direct DNA sequencing of amplified DNA fragments using 3 sets of primers covering the complete
HPV16 URR. DNA derived from laser-microdissected basal, intermediated and superficial layers of the cervical epithelium with permissive HPV16
infection was amplified and cloned. 12 individual clones were sequenced to identify the presence and patterns of the methylated CpG dinucleotides.
The Figure visualizes schematically the methylation of 16 CpG dinucleotides (positions from 7198 to 161) in the URR of HPV 16 genomes. Open circles
represent unmethylated CpGs, filled circles represent methylated CpGs.
doi:10.1371/journal.pone.0024451.g004
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permissive HPV infections or that stain positive for the L1 capsid
protein (Figure 1, Figures S1, S2 and S7) there are substantial
differences of the HPV methylome depending of the degree of
differentiation of the squamous epithelium. In the basal and
parabasal cells there is methylation of cellular transcription factor
binding sites within the viral enhancer element, whereas all E2BS
in the promoter and the 59upstream regulatory region are un-
methylated. With maturating differentiation the degree of
methylation of the transcription factor binding sites in DNA
isolated from the intermediate cell layers within the enhancer
region gradually decreased (Figure 4 and 6). In sharp contrast to
these findings, all CpGs in the viral promoter region were
completely methylated in DNA samples isolated from microdis-
sected superficial cells that displayed the fully differentiated
squamous epithelial phenotype and did express the late viral gene
product L1, whereas most other CpG dinucleotides remained
unmethylated even in the very superficial cells.
3.) The third major observation was that HPV-transformed
p16
INK4a-positive basal and parabasal squamous epithelial cells
(Figure 2, Figures S1, S3, S5, S8 and S10) consistently displayed
methylation of the two CpG dinucleotides within the E2BS1
(Figure 5 and 6). Taken together these data suggest that there are
distinct changes of the HPV methylome in relation to squamous
epithelial differentiation. Moreover the progression from non-
transforming infection modes (p16
INK4a-negative) to the trans-
forming infection mode (p16
INK4a overexpression in at least basal
and parabasal cells) was associated with the consistent methylation
of two defined CpG dinucleotides within the E2BS1.
This was surprising, since the E2BS1 is known to activate the
HPV URR [52–54]. Methylation of this site and reduced binding
of E2 to this site was thus expected to suppress the activity of the
HPV 16 URR. This in turn should have resulted in decreased but
not increased expression of the downstream early genes E6 and E7
as it is consistently observed in the transforming (p16
INK4a-
positive) HPV 16 transcription mode. Transient transfection
experiments reported here with unmethylated and selectively
methylated E2BS1 revealed, however, that E2 dependent
activation of the methylated reporter construct was substantially
higher if compared to the unmethylated construct (Figure 7B, 7C
and 7E). Methylation of E2BS1 thus appears to significantly
increase the p97 promoter activity. This indeed shows that
methylation of the E2BS1 may result in strong activation instead
of inhibition of the HPV 16 URR. This is in line with the
consistent observation that the shift towards the transformation is
characterized by enhanced expression of the E6 and E7 genes in
basal and parabasal squamous epithelial cells. Interestingly, a
recent report also suggested that CpG methylation in another
context may create binding sites with altered binding features and
may lead to substantial activation of the respective promoter
elements [55].
To test whether the observed methylation of the 2 CpG
dinucleotides within the E2BS1 may indeed affect the binding
properties of putative cellular transcription factors we performed
Figure 5. HPV16 URR methylation in the transforming infections. The methylation status of the HPV16 URR determined by bisulfite
treatment followed by direct DNA sequencing of amplified DNA fragments using 3 sets of primers covering the complete HPV16 URR. DNA derived
from laser-microdissected p16
INK4a-positive transformed epithelium was amplified and cloned. 12 individual clones were sequenced to identify the
presence and patterns of the methylated CpG dinucleotides. The Figure visualizes schematically the methylation of 16 CpG dinucleotides (positions
from 7198 to 161) in the URR of HPV 16 genomes. Open circles represent unmethylated CpGs, filled circles represent methylated CpGs.
doi:10.1371/journal.pone.0024451.g005
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methylated E2BS1 attracted a protein complex that may be
involved in the substantially altered transcriptional regulatory
features of this part of the HPV 16 URR found in the transforming
mode of HPV infections. This complex is currently being
investigated in detail in ongoing experimental work.
Taken together, the data presented here demonstrate that shifts
of the HPV methylome are linked to the various stages of
squamous epithelial differentiation. Moreover, the transition
towards the transforming mode of HPV infections appear to be
linked to distinct shifts of the methylation pattern in the HPV
URR that are apparently activating it and may provide a
molecular explanation for the substantially enhanced expression




From the archive of a large clinical pathology laboratory we
collected paraffin blocks of sections that displayed all stages of an
HPV infection, i.e. CIN 1, CIN 2 and CIN 3 lesions as well as
adjacent histologically normal mucosa. DNA was isolated using
QIAamp DNA FFPE Tissue Kit (Qiagen). HPV detection and
genotyping was performed using the Multiplex HPV genotyping
Kit according to the manufacturer’s instructions (Multimetrix
GmbH, Regensburg). After PCR amplification, the fluorescence-
labeled bead-bound probes were measured in a Luminex LX 100
analyzer. From these samples only the HPV 16 positive were
selected and prepared for microdissection. Recruitment of the
samples was part of an on-going study to identify molecular
parameters of persistent HPV infections that was approved by the
ethics committee of the Landesa ¨rztekammer Baden-Wu ¨rttemberg
(136/95). All samples used in this study were retrieved from a
routine pathology archive in a completely anonymous way. There
was no possibility for the laboratory performing the research
investigation to track back the identity of the respective patients.
They were older than three years and supposed to be discarded as
part of the routine diagnostic process. It was therefore not possible
to obtain written informed consent of the patients.
Immunohistochemistry and Microdissection
Polyethylene membranes (SL-Microtest, Jena, Germany) were
cut to size and mounted on non-charged Superfrost Color glass
Figure 6. Schematic representation of the relative methylation frequencies of 16 CpG nucleotides within the HPV16 URR. The degree
of methylation of 12 independent clones each isolated from basal, intermediate and superficial cell layers from the three latent, permissive and five
transforming parts of the cervical epithelium investigated by genomic sequencing as shown in Figure 3, 4 and 5. The y-axis shows the mean
percentage of methylated HPV16 genomes at each of the 16 CpG dinucleotides 6 standard deviation (SD). Mean values and SDs (three independent
lesions per each CpG) were calculated from Sigma Plot 10.0. Nucleotide numbers refer to those of the HPV16 reference clone (GenBank NC_001526).
doi:10.1371/journal.pone.0024451.g006
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immunohistochemistry staining were treated with 8% 3-amino-
propyltriethoxysilane (APES) solution in acetone. Serial 5-mm
paraffin sections were cut with a fresh knife, mounted on prepared
slides, and incubated at 60uC for 2 hours to achieve better tissue
adhesion to the membrane. Deparaffinization was carried out by
incubation in xylene (7 minutes), followed by washing and
rehydration in ethanol (99.9% ethanol 5 minutes, 96% ethanol
5 minutes, 70% ethanol 5 minutes). Immunhistochemical staining
for the expression of p16
INK4a was performed using the CINtec
p16
INK4a Histology kit for manual staining (mtm laboratories,
Heidelberg, Germany) according to manufacturer’s instructions.
Cytospin preparations of the HPV18 positive cervical cancer cell
line HeLa were used as positive controls.
Immunostaining for L1 was perfomed using the Cytoactive kit
for HPV L1 (Cytoimmun Diagnostic GbmH, Pirmanses, Ger-
many) as prescribed by the manufacturer. Counterstaining was
performed with Mayer’s Hematoxylin (DakoCytomation).
Selected p16
INK4a-positive clusters, as well as p16
INK4a-negative
non-tumour tissue (basal, parabasal, and superficial) cells, were
collected separately in the cap of a microfuge tube by laser
pressure catapulting using the PALMH Robot-Micro Beam for
microdissection.
DNA preparations and mapping of methylated CpGs in
the URR of HPV16
DNA was isolated using QIAamp DNA FFPE Tissue Kit
(Qiagen). The methylation status of the HPV16 URR was
determined by bisulfite treatment. Genomic DNA from microdis-
sected specimen or cell line was bisulfite-modified using the EZ
DNA methylation kit (Zymo Research, Orange, CA) according to
the manufacturer’s instructions. One microgram of DNA from the
Caski and SiHa cell lines was used as control and treated
concurrently with the samples to ensure complete bisulfite
treatment. After treatment, the resulting bisulfite-modified DNA
Figure 7. Methylation of the E2BS1 increases the p97 promoter activity. A. To measure the impact of methylation of the E2BS1 on the p97
promoter activity site specific modifications within the E2BS1 of LCR HPV16 of pGLuc reporter vector construct were generated using modified
oligonucleotides. Three constructs containing either an unmethylated (wt E2BS1), a mutated (mutE2BS1) or a methylated (methE2BS1) E2BS1 were
used. B and C. These plasmid constructs were co-transfected into C33A and NHK cells and increasing amount of E2 expression vector. The secreted
Gaussia luciferase activities were normalized using the corresponding internal ß-galactosidase activities. Each value represents the mean 6standard
deviation of at least three independent transfection experiments, each performed in triplicate. D. To analyze the impact of methylation of E2BS1 on
the early promoter activity in the natural context of the HPV 16 genome where E2 expression is under control of the p97 early promoter, NHK were
transiently transfected with full length HPV16 genome (wt or methylated E2BS1). E. The effect of selective E2BS1 methylation in full-length HPV16 on
E6 gene expression was measured by real-time PCR. Wild type and HPV16 full-length genome and the full length HPV16 genome with 2 selectively
methylated CpGs within E2BS1 were transfected into normal human foreskin keratinocytes (NHK.f.). Total RNA from cells 24, 48 and 72 hours after
transfection was assayed for the expression of E6 mRNA. Relative luciferase activities were calculated with respect to the values of the wt construct,
which was set to 1, for each time point. The data represent the mean of four independent experiments performed with each sample in triplicate with
error bars indicating 6 S.D. Mean values and SDs were calculated from Sigma Plot 10.0. F. To test whether methylation recruits other binding of
transcription factors to the region of E2BS1, we performed EMSA analysis using nuclear cell extracts isolated from NHK. Methylated and unmethylated
DNA probes spanning the regions containing the E2BS1 were used. The methylated probes showed three shifted bands by adding nuclear cell
extracts (line 4, 6). Unmethylated probes were not shifted by the same nuclear extract (lane 3, 5). Competition experiments were performed with non-
labeled probes (lines 7 and 8).
doi:10.1371/journal.pone.0024451.g007
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Five microliter of the bisulfite-modified DNA was used for each
PCR reaction. A nested PCR system was developed using primers
that span the URR of HPV 16 (from nt 7198 to nt 161;
NC_001526) (Table 1.).
PCR reaction mixtures were performed in a total of 50 ml
containing 106 PCR buffer, 1.5 ml 50 mM MgCl2,1ml1 0m M
deoxynucleotide triphosphates, 0.5 ml of each PCR primer
(25 mM) , 2.0 U Platinum Taq (Invitrogen) and 5 ml of the
bisulfite modified DNA. Amplification conditions were as follows:
initial denaturation at 94uC for 2 min followed by 40 cycles and 30
cycles for the nested PCR of 94uC for 40 s, annealing at 50uC for
30 s, extension at 72uC for 1 min and finally 72uC for 4 min. PCR
products were electrophoresed and isolated from 1.2% agarose
gels stained with ethidium bromide. Isolated PCR products were
then purified by QIAquick Gel Extraction Kit (Qiagen, Hilden)
according to the manufacturer’s instructions. Purified PCR
fragments were cloned the TA Cloning System (Invitrogen) and
12 individual clones were sequenced to identify the presence of
methylated CpGs within the HPV 16 LCR. Sequencing of bisulfite
modified sample DNA was performed using the BigDye
terminator sequencing kit (Applied Biosystems, Foster City, CA)
according to the manufacturer’s recommendations. The sequenc-
ing PCR products were analyzed on the ABI Prism 3100 Genetic
Analyzer. The degree of methylation of the 12 independent clones
each isolated from basal, intermediate and superficial cell layers
from the three latent, three permissive and 5 transforming
epithelial regions was analyzed by using the Systat statistical data
evaluation software (SigmaPlot version 10.0).
Analysis of the methylation status of the HPV16 E2BS1
using the Combined Bisulfite Restriction Analysis
(COBRA)
In order to determine the methylation status of the E2BS1
[7450-acCGaattCGgt-7461], distal to p97 promoter of HPV16 we
used modified Combined Bisulfite Restriction Analysis (COBRA)
[46]. DNA isolated from p16
INK4a-positive and p16
INK4a-negative
regions was bisulfite treated using the EZ DNA methylation kit
(Zymo Research, Orange, CA) according to the manufacturer’s
recommendations. After treatment, 5 ml of aliquot were amplified
in 50 ml of solution containing 16 buffer, 1.25 mM deoxynucle-
otide triphosphate mixtures, 2.5 pmol of each primer, and 1.5 unit
of Taq DNA polymerase (Life Technologies, Inc.). PCR was
carried out as follows. After a hot start, the cycling parameters
were: 94uC for 40 s, 50uC for 30 s, and 72uC for 60 s for 45 cycles
and final elongation at 72uC for 4 min. Primers used for COBRA
were as follows: HPV16-E2BS1for 59-AATTGTGTTGTGGT-
TATTTATTG-39 and HPV16-E2BS1rev 5-CAAATTTAAAC-
CATAATTACTAAC-39. After amplification, PCR products were
digested with the restriction enzyme EcoRI (New England
Biolabs). The EcoR I recognizes E2BS1 sequences unique to the
methylated and bisulfite-converted DNA. DNA was electropho-
resed in 2% agarose gels. The gels were stained with ethidium
bromide.
Generation of constructs
The LCR (nt 7008–124) of the HPV16 reference clone
(sequence identical to that published in the GenBank under the
accession number NC_001526) was PCR-amplified with Pfu
polymerase (Stratagene) and specific primers containing restriction
enzyme recognition sequences for HindIII (59-ATCAAGCTT-
GACCTAGATCAGTTTCCTTTAGGAC-39), and BamHI (59-
ATCGGATCCTCCTGTGGGTCCTGAAACATTGCAG-39).
Restriction-digested PCR products were cloned into pGLuc-Basic
Vector (New England Biolabs) giving pGLuc-LCR16 reporter
vector construct. The constructs were verified by DNA sequenc-
ing. Site specific modifications within the LCR HPV16 of pGLuc-
LCR16 reporter vector construct at the 7450-acCGaattCGgt -
7461 site was generated using modified oligonucleotides purchased
from Thermo Scientific. Modified oligonucleotides contained




CATGC-39) or an unmethylated (59-GCTTCAACCGAATTCG-
GTTGCATGC-39) CpG dinucleotides at the site of interest and
spanned 25 bps on either side of the site. PCR was carried out
according to the protocol in the QuickChange site-directed
mutagenesis kit (Stratagene) using 1 ng/reaction of the LCR
HPV16 luciferase reporter as template. Following PCR the
reaction was treated with DpnI for one hour to ensure that the
plasmid used for template was digested. Products were purified
using the PCR purification kit (Qiagen). Concentrations of the
product were determined by ethidum bromide gel electrophoresis
quantification. These products were then used directly for
transfection using Fugene HD method (Roche Applied Science).
In vitro DNA methylation was accomplished with CpGmethy-
lase (SssI methyltransferase), by following the procedure recom-
mended by New England Biolabs, the commercial provider of
SssI. Completion of DNA methylation was assessed by digestion
with the Hpa II restriction enzyme, which cleaves at its recognition
sequence only if the DNA is not methylated at the cytosine residue
within it.
For the generation of methylated and unmethylated LCR
HPV16 containing DNA fragments, the double-stranded LCR 16
DNA fragment, which was or was not subjected to in vitro
methylation with the SssI CpGmethylase, was cloned into the
HindIII and BamHI-linearized reporter plasmid pGluc-promoter
(New England Biolabs). Ligated products were purified using the
PCR purification kit (Qiagen). Two micrograms of the ligated
products generated with methylated or unmethylated LCR was
transfected into C33A cells. Mammalian expression vector
pFLAG-CMV-3 (Sigma) was used to express FLAG-tagged E2
HPV16 protein. The plasmid pFLAG-CMV-3-E2HPV16 was
constructed by cloning the HPV-16 E2 open reading frame,
generated by PCR amplification using low-grade HPV16 positive
cervical lesions as template with a HindIII site-containing sense
primer (59-ATCAAGCTTATGGAGACTCTTTGCCAACG-39)
and a BamHI site-containing antisense primer (59-ATCG-
GATCCTGTCATATAGACATAAATCCAG-39) into pFLAG-
Table 1. Primers used for bisulfite genomic sequencing of
the HPV16 URR.
Primer Sequence 59 to 39
59 LCR 59 LCR16 _for TTTGTATGTGTTTGTATGTGT
59 LCR16 _rev1 TTAAACCATAATTACTAACATAA
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with anti-FLAG M2 antibodies (Sigma) (Figure S11).
Cell culture, transfections and luciferase assay
Normal human keratinocytes (Promocell) were grown in K-SFM
keratinocytes defined serum-free medium (Invitrogen).http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=1462964 - R10
The human cervical cancer derived cell line C33A was grown in
Dulbecco’s modified Eagle medium supplemented with 10% fetal
bovine serum.Cells were transfectedby a method using Fugene HD
(Roche) liposomes as specified by the manufacturer. Secreted
Gaussia luciferase activity was determined using the Gaussia
Luciferase Assay Kit (New England Biolabs), according to the
manufacturer’s instructions. To avoid harvesting luciferase activity
from detached cells, supernatants were spun at 14,000 rpm for
5 minutes. 10–20 ml of supernatant from a 48-well plate (total
volume 0.5 ml) was added to 100 ml of GLuc Substrate prior to
analysis in a luminometer (Tecan 3010). The pSV-ß-Galactosidase
Control Vector (Promega) was used as ß-galactosidase internal
controls for transfection efficiency, and all luciferase activity
measurements were corrected for ß-galactosidase activity.
Real time RT-PCR
Total RNA was isolated with RNeasy kit (Qiagen). 1 mg of total
RNA was used for synthesis of first strand cDNA with random
primer and the Superscript III system (Invitrogen). Each 20 ml real
time Q-PCR reaction mixture contained 16SYBRH Green PCR
Master Mix (Applied Biosystems, Foster City, CA), 2.5 ml of cDNA
and 0.3 mM of each primer. E6 gene expression was quantified
using with E6 forward (59-AAGCAACAGTTACTGCGACGT-
GAG-39) and E6 reverse (59-CGGTCCACCGACCCTTA-
TATT-39) primers. The beta-actin gene was used as a reference.
The amplification was carried out according to the conditions
suggested by the manufacturer (initial denaturation at 95uC for
10 min and 40 cycles of 95uC for 15 s and 60uC for 1 min) using
an ABI Prism 7700 Sequence Detection System (Applied
Biosystems, Foster City, CA). Each measurement was performed
in triplicate and the threshold cycle numbers (Ct) were measured.
The copy number was generated from the Ct value.
Electromobility shift assay (EMSA)
For EMSA, complementary 25-mer methylated oligonucleo-
tides, including E2BS 1 (most distal to the P97 promoter of HPV-
16; E2BS1 sense, 59-GCTTCAAC
MCGAATT
MCGGTTG-





end-labeled with biotin using a biotin 39-end DNA-labeling kit
(Pierce) and annealed. The unmethylated probes were assembled
with two complementary oligonucleotides of identical sequence
except that cytosine replaced 5-methylcytosine on both strands.
Binding reactions were carried out by using a Light Shift
chemiluminescent electrophoretic mobility shift assay (EMSA) kit
(Pierce) according to the manufacturer’s instructions. Twenty-
microliter reaction mixtures containing 10 mM Tris, 50 mM KCl,
1 mM dithiothreitol, 50 ng of poly(dI-dC)/ml and 5–10 mgo f
nuclear extract , and 20 fmol labeled, double-stranded oligonu-
cleotide were incubated for 30 min at room temperature. Reaction
mixtures lacking protein or containing cold competitor (4 pmol
unlabeled oligonucleotide) were included as controls. Reaction
products were resolved on 6% Tris-borate-EDTA-polyacrylamide
gels at 90 V in 0.5% Tris-borate-EDTA buffer: 100 mMTrisHCl,
100 mM borate, and 2 mM EDTA, pH 8.3. Proteins were then
transferred to Hybond N+ (Amersham Pharmacia Biotech), and
biotinylated DNA was detected by chemiluminescence per the
manufacturer’s instructions.
Supporting Information
Figure S1 Sample N1. Regions with HPV16 permissive and
transforming infections. Before and after microdissection (left
upper and lower images). The p16
INKa-negative region displaying
koilocytes (upper,right image) and L1 expression (lower right
image) as indicator for permissive infection. This area corresponds
in pathology terms to a flat condyloma.
(TIF)
Figure S2 Sample N2. Region with HPV16 permissive
infection. Before and after microdissection (left upper and lower
images). The p16
INKa -negative region displaying koilocytes (upper
right image) and L1 expression (lower right image) as indicator for
permissive infection. The p16
INK4a-negative parts here again
correspond to a flat condyloma.
(TIF)
Figure S3 Sample N2. Region with HPV16 transforming
infection. Before and after microdissection (left upper and lower
images). The p16
INKa positive region (right image) of transformed
epithelium.
(TIF)
Figure S4 Sample N1. Region with HPV16 latent infection.
Before and after microdissection. The p16
INKa-negative region
without morphological changes of the epithelium and no signs of
the viral replication (no koilocytes and no L1 expression).
(TIF)
Figure S5 Sample N3. Region with HPV16 transforming
infection. Before and after microdissection. The p16
INKa-positive
region (right image) of transformed epithelium.
(TIF)
Figure S6 Sample N2. Region with HPV16 latent infection.
Before and after microdissection. The p16
INKa-negative region
without morphological changes of the epithelium and no signs of
the viral replication (no koilocytes and no L1 expression).
(TIF)
Figure S7 Sample N3. Region with HPV16 permissive
infection. Before and after microdissection (left upper and lower
images). The p16
INKa-negative region displaying koilocytes (upper
right image) and L1 expression (lower right image) as indicator for
permissive infection, corresponding again to a flat condyloma.
(TIF)
Figure S8 Sample N4. Region with HPV16 transforming
infection. Before and after microdissection. The p16
INKa -positive
region (right image) of transformed epithelium.
(TIF)
Figure S9 Sample N3. Region with HPV16 latent infection.
Before and after microdissection. The p16
INKa-negative region
without morphological changes of the epithelium and no signs of
the viral replication (no koilocytes and no L1 expression).
(TIF)
Figure S10 Sample N5. Region with HPV16 transforming
infection. Before and after microdissection. The p16
INKa-positive
region (right image) of transformed epithelium.
(TIF)
Figure S11 Expression of HPV-16 E2 protein in C33A
cells. The HPV 16 E2 protein was expressed from the pFLAG-
CMV-3 vector. After 48 h of incubation, the transfected cells were
The HPV-Methylome in the HPV Life Cycle
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24451disrupted in 200 ml of lysis buffer. Forty microliters of each lysate
was subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred to a nitrocellulose membrane.
The E2 proteins were detected by anti-FLAG M2 antibodies.
(TIF)
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